课题基金 / 基金详情

Antiestrogen Regulation of Bladder Cancer

Antiestrogen Regulation of Bladder Cancer
膀胱癌的抗雌激素调节
批准号:
7471237
负责人:
CAROLYN Louise SMITH
金额:
$7.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-01 至 2010-05-31

项目摘要

项目成果

CAROLYN Louise SMITH的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 膀胱癌是美国第四大常见癌症,每年新增病例超过63,210例,相关死亡13,180例。值得注意的是,男性的膀胱癌发病率是女性的三倍。已知雌激素受体介导雌激素的细胞内作用。雌激素受体-a(Era)和雌激素受体(ER)两种受体亚型介导对雌激素和抗雌激素的核/基因组反应,它们既有独立的组织分布和功能,也有重叠的组织分布和功能。ERA和ER在人膀胱上皮和逼尿肌中的表达已有报道,在大鼠和小鼠的研究表明,ER主要在膀胱上皮和逼尿肌中表达。采用配体结合分析的实验表明,ERs在人类膀胱移行细胞癌中存在,免疫学方法表明ERa在12%-18%的被测膀胱癌中表达。然而,这与膀胱癌患者的预后无关。我们已经产生的数据表明:1)ER?在大多数人的膀胱移行细胞癌中表达,具有广泛的分期和分级特征,而ERA在5%的肿瘤中表达;2)ER?在多个被测的膀胱癌细胞系中表达;3)选择性雌激素受体调节剂(SERM),雷洛昔芬和他莫昔芬,在体外抑制膀胱癌细胞系的生长;4)雷洛昔芬和4-羟基他莫昔芬,减少膀胱癌裸鼠移植瘤的体积。基于这些发现,我们提出了以下假设。SERM对膀胱癌细胞株的作用主要是由ER介导的,ER是人膀胱癌中表达的ER的主要亚型。对ER阳性的膀胱细胞进行SERM治疗将抑制其生长,因此将是膀胱癌的有效化学预防策略。这一假说将在以下两个特定的目的进行验证:1)研究雌激素受体的作用和雌激素受体配体对膀胱癌细胞生长的调节作用;2)在人膀胱癌原位模型中研究选择性雌激素受体调节剂的体内抗肿瘤作用。
英文摘要
DESCRIPTION (provided by applicant): Bladder cancer is the fourth most common cancer occurring in the United States, with each year bringing more than 63,210 new cases and 13,180 related deaths. Notably, the incidence of bladder cancer is three times higher in men than women. Estrogen receptors are known to mediate the intracellular actions of estrogens. Two receptor subtypes, estrogen receptor-a (ERa) and ER¿ mediate the nuclear/genomic responses to estrogens and antiestrogens, and they exhibit both separate and overlapping tissue distributions and functions. Expression of ERa and ER¿ have been reported in the urothelium and detrusor muscle of the human bladder, and studies in rats and mice indicate that ER¿ is the predominant form of ER expressed in the bladder epithelium and smooth muscle. Experiments employing ligand binding analyses indicate that ERs are present in transitional cell carcinoma of bladder in humans, and immunological approaches demonstrate ERa expression in 12%-18% of tested bladder cancers. This, however, did not correlate with the prognosis of bladder cancer patients. We have generated data indicating that: 1) ER¿ is expressed in the majority of human bladder transitional cell cancers across a broad spectrum of stage and grade, while ERa is expressed in < 5% of tumors; 2) ER¿ is expressed in multiple bladder cancer cell lines tested; 3) the selective estrogen receptor modulators (SERMs), raloxifene and tamoxifen, inhibit growth of bladder cancer cell lines in vitro and 4) raloxifene and 4- hydroxytamoxifen reduce the size of bladder cancer xenografts grown in female nude mice. Based on these findings we propose the following hypothesis. SERM effects on bladder cancer cell lines are mediated mainly by ER¿ which is the predominate isoform of the ER expressed in human bladder cancer. SERM treatment of ER¿-positive bladder cells will inhibit their growth, and therefore will be an effective chemoprevention strategy for bladder cancer. This hypothesis will be tested in the following two specific aims: 1) To investigate the role of estrogen receptor and the ability of estrogen receptor ligands to regulate bladder cancer cell growth, and 2) To study the in vivo anti-tumor effect of selective estrogen receptor modulators in an orthotopic model of human bladder cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Clinical Translational Research Certificate of Added Qualification Program
  • 批准号:
    10192765
  • 项目类别:
  • 资助金额:
    $43.89万
  • 财政年份:
    2020
  • 负责人:
    CAROLYN Louise SMITH
  • 依托单位:
The Clinical Translational Research Certificate of Added Qualification Program
  • 批准号:
    10654873
  • 项目类别:
  • 资助金额:
    $42.44万
  • 财政年份:
    2020
  • 负责人:
    CAROLYN Louise SMITH
  • 依托单位:
The Clinical Translational Research Certificate of Added Qualification Program
  • 批准号:
    10440362
  • 项目类别:
  • 资助金额:
    $46.83万
  • 财政年份:
    2020
  • 负责人:
    CAROLYN Louise SMITH
  • 依托单位:
Antiestrogen Regulation of Bladder Cancer
  • 批准号:
    7622145
  • 项目类别:
  • 资助金额:
    $7.68万
  • 财政年份:
    2008
  • 负责人:
    CAROLYN Louise SMITH
  • 依托单位:
海外基金